A phase I trial of dasatinib, an Src-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5489-5498

  Secord, Angeles Alvarez ^a   Teoh, Deanna K ^a   Barry, William T ^a   Yu, Miao ^a   Broadwater, Gloria ^a   Havrilesky, Laura J ^a   Lee, Paula S ^a   Berchuck, Andrew ^a   Lancaster, Johnathan ^b   Wenham, Robert M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DASATINIB; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; ELECTROLYTE DISTURBANCE; EPISTAXIS; EYE DISEASE; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; GASTRITIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LIMB PAIN; LUNG DISEASE; LUNG TOXICITY; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEURALGIA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVERALL SURVIVAL; PAIN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SENSORY NEUROPATHY; SIDE EFFECT; SINUS PAIN; SOMNOLENCE; SORE THROAT; STOMACH DISTENSION; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 84866943631     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0507     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 2003;309:377-83. (Pubitemid 37025902)
3. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 2005;4:217-24. (Pubitemid 40340201)
4. Teoh D, Ayeni TA, Rubatt JM, Adams DJ, Grace L, Starr MD, et al. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. Gynecol Oncol 2011;121:187-92.
5. George JA, Chen T, Taylor CC. Src tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res 2005;65:10381-8. (Pubitemid 41743731)
6. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC, Gallick GE. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 1999;5:2164-70. (Pubitemid 29399273)
7. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006;66:8633-9. (Pubitemid 44449178)
8. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61. (Pubitemid 40053752)
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
10. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-91.
11. National Cancer Institute [Internet]. U.S. National Institutes of Health: Center for Cancer Research; [cited 2012 Apr 26]. Available from: http://nciarray.nci.nih.gov/reference/.
12. Irizarry RA BB, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
13. Smyth GK. Limma: Linear models for microarray data. In:Gentleman R, Carey V, Huber W, Irizarry RA, Dudoit S, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 397-420.
14. Benjamini Y, Yekutieli D. False discovery rate-adjusted multiple confidence intervals for selected parameters. J Amer Statist Assoc 2005;100:71-93. (Pubitemid 40366820)
15. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
16. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A 2010;107:6994-9.
17. Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, et al. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer 2009;101:1699-1708.
18. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38. (Pubitemid 46424242)
19. Barry WT, Nobel AB, Wright FA. Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics 2005;21:1943-9. (Pubitemid 40668030)
20. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. Gene-Pattern 2.0. Nat Genet 2006;38:500-1.
21. National Center for Biotechnology Information[Internet]. Bethesda (MD): Gene Expression Omnibus. c2012- [cited 2012 Apr 12]. Available from: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37180.
22. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-6.
23. Investigator Brochure Dasatinib BMS-354825, Version 10 2010.
24. Poole C, Lisyanskaya A, Rodenhuis S, Kristensen G, Pujade-Lauraine E, Cantarini M, et al. A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin 1 paclitaxel (C1P) versus C1P in patients with advanced platinum-sensitive epithelial ovarian cancer. Ann Oncol 2010;21 Suppl 8: S313.
25. Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, et al. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. Mol Biol Cell 2000;11:3835-48.
26. Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 2007;282:5413-9. (Pubitemid 47093772)
27. Zhang X, Arnott JA, Rehman S, Delong WG Jr, Sanjay A, Safadi FF, et al. Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts. J Cell Physiol 2010;224:691-701.